PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury

Experimental and Molecular Medicine

Volumn 45, Issue 11, 2013, Pages

  Yang, Han Mo ^a,b   Kim, Baek Kyung ^a,b   Kim, Ju Young ^a,b   Kwon, Yoo Wook ^a,b   Jin, Sooryeonhwa ^a,b   Lee, Joo Eun ^a,b   Cho, Hyun Jai ^a,b   Lee, Hae Young ^a,b   Kang, Hyun Jae ^a,b   Oh, Byung Hee ^a,b   Park, Young Bae ^a,b   Kim, Hyo Soo ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

CGMP dependent protein kinase; Rosiglitazone; Smooth muscle cells

Indexed keywords

CALPONIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; ROSIGLITAZONE; THROMBOSPONDIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACTIN BINDING PROTEIN; CALCIUM BINDING PROTEIN; TRANSCRIPTION FACTOR SP1;

ANGIOPLASTY; ANIMAL CELL; ARTICLE; CAROTID ARTERY INJURY; ENZYME ACTIVATION; ENZYME ACTIVITY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEOINTIMA; NEOINTIMAL HYPERPLASIA; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; AGONISTS; ANIMAL; AORTA; BLOOD VESSEL INJURY; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; INTIMA; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; DRUG EFFECT; DRUG POTENTIATION; INJURY;

ANIMALS; AORTA; CALCIUM-BINDING PROTEINS; CELL PROLIFERATION; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HYPERPLASIA; MICROFILAMENT PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; PPAR GAMMA; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; SP1 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; THROMBOSPONDINS; TUNICA INTIMA; VASCULAR SYSTEM INJURIES;

EID: 84892182748     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.112     Document Type: Article

References (34)

1. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-Atherogenic agents. Diabetes Metab Res Rev 2008; 24: 14-26.
2. Khanderia U, Pop-Busui R, Eagle KA. Thiazolidinediones in type 2 diabetes: A cardiology perspective. Ann Pharmacother 2008; 42: 1466-1474.
3. Krentz A. Thiazolidinediones: Effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes Metab Res Rev 2009; 25: 112-126.
4. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008; 9: 1087-1108.
5. Sarafidis PA. Thiazolidinedione derivatives in diabetes and cardiovascular disease: An update. Fundam Clin Pharmacol 2008; 22: 247-264.
6. Lin G, Chow S, Lin J, Wang G, Lue TF, Lin CS. Effect of cell passage and density on protein kinase G expression and activation in vascular smooth muscle cells. J Cell Biochem 2004; 92: 104-112.
7. Yoshida T, Owens GK. Molecular determinants of vascular smooth muscle cell diversity. Circ Res 2005; 96: 280-291.
8. Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U. Physiology and pathophysiology of vascular signaling controlled by guanosine 30,50-cyclic monophosphate-dependent protein kinase [corrected]. Circulation 2003; 108: 2172-2183.
9. Sachinidis A, Flesch M, Ko Y, Schror K, Bohm M, Dusing R et al. Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension 1995; 26: 771-780.
10. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004; 110: 301-308.
11. Park KW, Yang HM, Youn SW, Yang HJ, Chae IH, Oh BH et al. Constitutively active glycogen synthase kinase-3beta gene transfer sustains apoptosis, inhibits proliferation of vascular smooth muscle cells, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 2003; 23: 1364-1369.
12. Kawai-Kowase K, Owens GK. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol 2007; 292: C59-C69.
13. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
14. Boerth NJ, Dey NB, Cornwell TL, Lincoln TM. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J Vasc Res 1997; 34: 245-259.
15. Lincoln TM, Dey NB, Boerth NJ, Cornwell TL, Soff GA. Nitric oxide-cyclic GMP pathway regulates vascular smooth muscle cell phenotypic modulation: Implications in vascular diseases. Acta Physiol Scand 1998; 164: 507-515.
16. Dey NB, Foley KF, Lincoln TM, Dostmann WR. Inhibition of cGMPdependent protein kinase reverses phenotypic modulation of vascular smooth muscle cells. J Cardiovasc Pharmacol 2005; 45: 404-413.
17. Dey NB, Boerth NJ, Murphy-Ullrich JE, Chang PL, Prince CW, Lincoln TM. Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells. Circ Res 1998; 82: 139-146.
18. Sinnaeve P, Chiche JD, Gillijns H, Van Pelt N, Wirthlin D, Van De Werf F et al. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 2002; 105: 2911-2916.
19. Birschmann I, Walter U. Physiology and pathophysiology of vascular signaling controlled by guanosine 30,50-cyclic monophosphate-dependent protein kinase. Acta Biochim Pol 2004; 51: 397-404.
20. Ruth P, Pfeifer A, Kamm S, Klatt P, Dostmann WR, Hofmann F. Identification of the amino acid sequences responsible for high affinity activation of cGMP kinase Ialpha. J Biol Chem 1997; 272: 10522-10528.
21. Hofmann F, Ammendola A, Schlossmann J. Rising behind NO: CGMPdependent protein kinases. J Cell Sci 2000; 113: 1671-1676.
22. Phillips JW, Barringhaus KG, Sanders JM, Yang Z, Chen M, Hesselbacher S et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 2003; 108: 1994-1999.
23. Lee CS, Kwon YW, Yang HM, Kim SH, Kim TY, Hur J et al. New mechanism of rosiglitazone to reduce neointimal hyperplasia: Activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol 2009; 29: 472-479.
24. Deguchi A, Soh JW, Li H, Pamukcu R, Thompson WJ, Weinstein IB. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther 2002; 1: 803-809.
25. Chen L, Daum G, Chitaley K, Coats SA, Bowen-Pope DF, Eigenthaler M et al. Vasodilator-stimulated phosphoprotein regulates proliferation and growth inhibition by nitric oxide in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 1403-1408.
26. Sellak H, Yang X, Cao X, Cornwell T, Soff GA, Lincoln T. Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Ialpha expression in vascular smooth muscle cells. Circ Res 2002; 90: 405-412.
27. Zeng Y, Zhuang S, Gloddek J, Tseng CC, Boss GR, Pilz RB. Regulation of cGMP-dependent protein kinase expression by Rho and Kruppel-like transcription factor-4. J Biol Chem 2006; 281: 16951-16961.
28. Sellak H, Choi C, Browner N, Lincoln TM. Upstream stimulatory factors (USF-1/USF-2) regulate human cGMP-dependent protein kinase I gene expression in vascular smooth muscle cells. J Biol Chem 2005; 280: 18425-18433.
29. Tedeschi A, Nguyen T, Steele SU, Feil S, Naumann U, Feil R et al. The tumor suppressor p53 transcriptionally regulates cGKI expression during neuronal maturation and is required for cGMP-dependent growth cone collapse. J Neurosci 2009; 29: 15155-15160.
30. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-Traditional atherosclerotic risk factors. Int J Clin Pract 2009; 63: 912-929.
31. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
32. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5 A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222.
33. Garcia-Dorado D, Agullo L, Sartorio CL, Ruiz-Meana M. Myocardial protection against reperfusion injury: The cGMP pathway. Thromb Haemost 2009; 101: 635-642.
34. Hood J, Granger HJ. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem 1998; 273: 23504-23508.